Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2005-08-15

AUTHORS

Mario I Vega, Sara Huerta-Yepez, Ali R Jazirehi, Hermes Garban, Benjamin Bonavida

ABSTRACT

Rituximab (chimeric anti-CD20 monoclonal antibodies) is currently being used in the treatment of B non-Hodgkin's lymphoma (NHL). We have recently reported that rituximab triggers and modifies various intracellular signaling pathways in NHL B-cell lines, resulting in reverting the chemoresistant phenotype to a sensitive phenotype. This study investigated whether rituximab also modifies intracellular signaling pathways resulting in the sensitization of NHL cells to Fas-induced apoptosis. Treatment of the Fas-resistant NHL cell lines (2F7, Ramos and Raji) with rituximab sensitized the cells to CH-11 (FasL agonist mAb)-induced apoptosis and synergy was achieved. Fas expression was upregulated by rituximab as early as 6 h post-treatment as determined by flow cytometry, reverse transcriptase–polymerase chain reaction and Western blot. Rituximab inhibited both the expression and activity of the transcription repressor Yin-Yang 1 (YY1) that negatively regulates Fas transcription. Inhibition of YY1 resulted in the upregulation of Fas expression and sensitization of the tumor cells to CH-11-induced apoptosis. The downregulation of YY1 expression was the result of rituximab-induced inhibition of both the p38 mitogen-activated protein kinase (MAPK) signaling pathway and constitutive nuclear factor κ of B cells (NF-κB) activity. The involvement of NF-κB and YY1 in the regulation of Fas expression was corroborated by the use of Ramos cells with a dominant-active inhibitor of NF-κB (Ramos IκB-estrogen receptor (ER) mutant) and by silencing YY1 with YY1 siRNA, respectively. Further, the role of rituximab-mediated inhibition of the p38 MAPK/NF-κB/YY1 pathway in the regulation of Fas and sensitization to CH-11-induced apoptosis was validated by the use of specific chemical inhibitors of this pathway and which mimicked rituximab-mediated effects. These findings provide a novel mechanism of rituximab-mediated activity by sensitizing NHL cells to Fas-induced apoptosis. More... »

PAGES

8114-8127

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.onc.1208954

DOI

http://dx.doi.org/10.1038/sj.onc.1208954

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1001742245

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16103877


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Murine-Derived", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, CD20", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Burkitt Lymphoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Regulation, Neoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, AIDS-Related", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, B-Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "NF-kappa B", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcription, Genetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "fas Receptor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "p38 Mitogen-Activated Protein Kinases", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Unidad de Investigaction Medica en Inmunologia e Infectologia, Hospital de Infectologia, CMN \u2018La Raza\u2019, IMSS, Mexico", 
          "id": "http://www.grid.ac/institutes/grid.419157.f", 
          "name": [
            "Department of Microbiology, Immunology and Molecular Genetics, University of California, 10833 Le Conte Avenue, A2-060 CHS, 90095, Los Angeles, CA, USA", 
            "Unidad de Investigaction Medica en Inmunologia e Infectologia, Hospital de Infectologia, CMN \u2018La Raza\u2019, IMSS, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vega", 
        "givenName": "Mario I", 
        "id": "sg:person.01123230023.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123230023.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unidad de Investigaction Medica en Inmunologia e Infectologia, Hospital de Infectologia, CMN \u2018La Raza\u2019, IMSS, Mexico", 
          "id": "http://www.grid.ac/institutes/grid.419157.f", 
          "name": [
            "Department of Microbiology, Immunology and Molecular Genetics, University of California, 10833 Le Conte Avenue, A2-060 CHS, 90095, Los Angeles, CA, USA", 
            "Unidad de Investigaction Medica en Inmunologia e Infectologia, Hospital de Infectologia, CMN \u2018La Raza\u2019, IMSS, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huerta-Yepez", 
        "givenName": "Sara", 
        "id": "sg:person.01171343223.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171343223.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Microbiology, Immunology and Molecular Genetics, University of California, 10833 Le Conte Avenue, A2-060 CHS, 90095, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Microbiology, Immunology and Molecular Genetics, University of California, 10833 Le Conte Avenue, A2-060 CHS, 90095, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jazirehi", 
        "givenName": "Ali R", 
        "id": "sg:person.01016673065.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016673065.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Molecular and Medical Pharmacology, Jonnson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, 90095, Los AngelesCA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Microbiology, Immunology and Molecular Genetics, University of California, 10833 Le Conte Avenue, A2-060 CHS, 90095, Los Angeles, CA, USA", 
            "Department of Molecular and Medical Pharmacology, Jonnson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, 90095, Los AngelesCA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garban", 
        "givenName": "Hermes", 
        "id": "sg:person.0757645323.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757645323.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Microbiology, Immunology and Molecular Genetics, University of California, 10833 Le Conte Avenue, A2-060 CHS, 90095, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Microbiology, Immunology and Molecular Genetics, University of California, 10833 Le Conte Avenue, A2-060 CHS, 90095, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bonavida", 
        "givenName": "Benjamin", 
        "id": "sg:person.014442031637.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014442031637.81"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.onc.1207336", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011264195", 
          "https://doi.org/10.1038/sj.onc.1207336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1208349", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005063354", 
          "https://doi.org/10.1038/sj.onc.1208349"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1011158021749", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005577705", 
          "https://doi.org/10.1023/a:1011158021749"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002620050016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035594402", 
          "https://doi.org/10.1007/s002620050016"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02982645", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011206446", 
          "https://doi.org/10.1007/bf02982645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2401369", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018668097", 
          "https://doi.org/10.1038/sj.leu.2401369"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1207655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032441334", 
          "https://doi.org/10.1038/sj.onc.1207655"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-08-15", 
    "datePublishedReg": "2005-08-15", 
    "description": "Rituximab (chimeric anti-CD20 monoclonal antibodies) is currently being used in the treatment of B non-Hodgkin's lymphoma (NHL). We have recently reported that rituximab triggers and modifies various intracellular signaling pathways in NHL B-cell lines, resulting in reverting the chemoresistant phenotype to a sensitive phenotype. This study investigated whether rituximab also modifies intracellular signaling pathways resulting in the sensitization of NHL cells to Fas-induced apoptosis. Treatment of the Fas-resistant NHL cell lines (2F7, Ramos and Raji) with rituximab sensitized the cells to CH-11 (FasL agonist mAb)-induced apoptosis and synergy was achieved. Fas expression was upregulated by rituximab as early as 6\u2009h post-treatment as determined by flow cytometry, reverse transcriptase\u2013polymerase chain reaction and Western blot. Rituximab inhibited both the expression and activity of the transcription repressor Yin-Yang 1 (YY1) that negatively regulates Fas transcription. Inhibition of YY1 resulted in the upregulation of Fas expression and sensitization of the tumor cells to CH-11-induced apoptosis. The downregulation of YY1 expression was the result of rituximab-induced inhibition of both the p38 mitogen-activated protein kinase (MAPK) signaling pathway and constitutive nuclear factor \u03ba of B cells (NF-\u03baB) activity. The involvement of NF-\u03baB and YY1 in the regulation of Fas expression was corroborated by the use of Ramos cells with a dominant-active inhibitor of NF-\u03baB (Ramos I\u03baB-estrogen receptor (ER) mutant) and by silencing YY1 with YY1 siRNA, respectively. Further, the role of rituximab-mediated inhibition of the p38 MAPK/NF-\u03baB/YY1 pathway in the regulation of Fas and sensitization to CH-11-induced apoptosis was validated by the use of specific chemical inhibitors of this pathway and which mimicked rituximab-mediated effects. These findings provide a novel mechanism of rituximab-mediated activity by sensitizing NHL cells to Fas-induced apoptosis.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.onc.1208954", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2354610", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2438693", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1097543", 
        "issn": [
          "0950-9232", 
          "1476-5594"
        ], 
        "name": "Oncogene", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "55", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "keywords": [
      "Yin Yang 1", 
      "Fas expression", 
      "CH-11-induced apoptosis", 
      "NF-\u03baB", 
      "NHL cells", 
      "mitogen-activated protein kinase", 
      "Fas-induced apoptosis", 
      "B cell activity", 
      "inhibition of YY1", 
      "transcriptase-polymerase chain reaction", 
      "NHL B-cell lines", 
      "NHL cell lines", 
      "nuclear factor \u03ba", 
      "cell lines", 
      "transcription repressor Yin Yang 1", 
      "rituximab-mediated effects", 
      "B-NHL cell lines", 
      "Hodgkin's lymphoma", 
      "p38 mitogen-activated protein kinase", 
      "B cell lines", 
      "regulation of Fas", 
      "rituximab", 
      "specific chemical inhibitors", 
      "chemoresistant phenotype", 
      "YY1 expression", 
      "cell activity", 
      "flow cytometry", 
      "Western blot", 
      "tumor cells", 
      "Fas transcription", 
      "chain reaction", 
      "factor \u03ba", 
      "sensitization", 
      "lymphoma", 
      "apoptosis", 
      "YY1 siRNA", 
      "inhibition", 
      "Ramos cells", 
      "novel mechanism", 
      "CH-11", 
      "cells", 
      "treatment", 
      "chemical inhibitors", 
      "inhibitors", 
      "intracellular", 
      "expression", 
      "pathway", 
      "phenotype", 
      "sensitive phenotype", 
      "protein kinase", 
      "agonists", 
      "activity", 
      "cytometry", 
      "upregulation", 
      "downregulation", 
      "blot", 
      "siRNA", 
      "involvement", 
      "regulation", 
      "findings", 
      "use", 
      "FA", 
      "lines", 
      "kinase", 
      "triggers", 
      "study", 
      "transcription", 
      "role", 
      "effect", 
      "mechanism", 
      "synergy", 
      "results", 
      "reaction"
    ], 
    "name": "Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis", 
    "pagination": "8114-8127", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1001742245"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.onc.1208954"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16103877"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.onc.1208954", 
      "https://app.dimensions.ai/details/publication/pub.1001742245"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_408.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.onc.1208954"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1208954'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1208954'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1208954'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1208954'


 

This table displays all metadata directly associated to this object as RDF triples.

285 TRIPLES      22 PREDICATES      127 URIs      111 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.onc.1208954 schema:about N0b4693d27db04a09ad7d003ed4a549f0
2 N133a0b631b564fbcbbf042f8d67a42e5
3 N16452f1431594c868a9ad0c28a22cd50
4 N2385cbdae07543e9885cfdaa897845c8
5 N2879626b51564f6f82ebd94ec267dbb7
6 N3946abb3c5174223a7a15d9faaede197
7 N51f71d7481b047efafd5414bbf0adac2
8 N6563b4d65eca4361b9692a1812cd6e63
9 N87d21fbfea534619af5f4068928e69c8
10 N9a283ab4e3d047209a160299bbcd9a44
11 Nb3fb60e3c1fe42a9b37f329defb7c3e9
12 Nb99735ff2e524ff0bd0ce5e220ae35a3
13 Ncd09f32aa3464c4cb980158f70e5a76d
14 Ne4348b5870494e069dd5f3396391c916
15 Ne49c3ef878b84d5eab988d05472c5d08
16 Ne8aa938a8703469482d193d8bad2c97c
17 Neea33dfd643e49efae92bdf33118fac2
18 Nf1fb6ff0ed774bb3ad15e94e38cc0b0e
19 Nf51c62542b40466d9fbe9c6a2af434c7
20 Nff97f6cfde6d44d197e2db2ff0a7338f
21 anzsrc-for:11
22 anzsrc-for:1103
23 anzsrc-for:1112
24 schema:author Nfa5d939125df4920bc7794a0b548cb02
25 schema:citation sg:pub.10.1007/bf02982645
26 sg:pub.10.1007/s002620050016
27 sg:pub.10.1023/a:1011158021749
28 sg:pub.10.1038/sj.leu.2401369
29 sg:pub.10.1038/sj.onc.1207336
30 sg:pub.10.1038/sj.onc.1207655
31 sg:pub.10.1038/sj.onc.1208349
32 schema:datePublished 2005-08-15
33 schema:datePublishedReg 2005-08-15
34 schema:description Rituximab (chimeric anti-CD20 monoclonal antibodies) is currently being used in the treatment of B non-Hodgkin's lymphoma (NHL). We have recently reported that rituximab triggers and modifies various intracellular signaling pathways in NHL B-cell lines, resulting in reverting the chemoresistant phenotype to a sensitive phenotype. This study investigated whether rituximab also modifies intracellular signaling pathways resulting in the sensitization of NHL cells to Fas-induced apoptosis. Treatment of the Fas-resistant NHL cell lines (2F7, Ramos and Raji) with rituximab sensitized the cells to CH-11 (FasL agonist mAb)-induced apoptosis and synergy was achieved. Fas expression was upregulated by rituximab as early as 6 h post-treatment as determined by flow cytometry, reverse transcriptase–polymerase chain reaction and Western blot. Rituximab inhibited both the expression and activity of the transcription repressor Yin-Yang 1 (YY1) that negatively regulates Fas transcription. Inhibition of YY1 resulted in the upregulation of Fas expression and sensitization of the tumor cells to CH-11-induced apoptosis. The downregulation of YY1 expression was the result of rituximab-induced inhibition of both the p38 mitogen-activated protein kinase (MAPK) signaling pathway and constitutive nuclear factor κ of B cells (NF-κB) activity. The involvement of NF-κB and YY1 in the regulation of Fas expression was corroborated by the use of Ramos cells with a dominant-active inhibitor of NF-κB (Ramos IκB-estrogen receptor (ER) mutant) and by silencing YY1 with YY1 siRNA, respectively. Further, the role of rituximab-mediated inhibition of the p38 MAPK/NF-κB/YY1 pathway in the regulation of Fas and sensitization to CH-11-induced apoptosis was validated by the use of specific chemical inhibitors of this pathway and which mimicked rituximab-mediated effects. These findings provide a novel mechanism of rituximab-mediated activity by sensitizing NHL cells to Fas-induced apoptosis.
35 schema:genre article
36 schema:inLanguage en
37 schema:isAccessibleForFree true
38 schema:isPartOf N3461d55cc1114354b769b84d26aaa5d0
39 Nb2ea058f213d4271aefcd43d3dba6f5b
40 sg:journal.1097543
41 schema:keywords B cell activity
42 B cell lines
43 B-NHL cell lines
44 CH-11
45 CH-11-induced apoptosis
46 FA
47 Fas expression
48 Fas transcription
49 Fas-induced apoptosis
50 Hodgkin's lymphoma
51 NF-κB
52 NHL B-cell lines
53 NHL cell lines
54 NHL cells
55 Ramos cells
56 Western blot
57 YY1 expression
58 YY1 siRNA
59 Yin Yang 1
60 activity
61 agonists
62 apoptosis
63 blot
64 cell activity
65 cell lines
66 cells
67 chain reaction
68 chemical inhibitors
69 chemoresistant phenotype
70 cytometry
71 downregulation
72 effect
73 expression
74 factor κ
75 findings
76 flow cytometry
77 inhibition
78 inhibition of YY1
79 inhibitors
80 intracellular
81 involvement
82 kinase
83 lines
84 lymphoma
85 mechanism
86 mitogen-activated protein kinase
87 novel mechanism
88 nuclear factor κ
89 p38 mitogen-activated protein kinase
90 pathway
91 phenotype
92 protein kinase
93 reaction
94 regulation
95 regulation of Fas
96 results
97 rituximab
98 rituximab-mediated effects
99 role
100 sensitive phenotype
101 sensitization
102 siRNA
103 specific chemical inhibitors
104 study
105 synergy
106 transcriptase-polymerase chain reaction
107 transcription
108 transcription repressor Yin Yang 1
109 treatment
110 triggers
111 tumor cells
112 upregulation
113 use
114 schema:name Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis
115 schema:pagination 8114-8127
116 schema:productId N17062abb28fc4cd796ae5703bf198aed
117 N45f77158cfd7437687aa4930f188469e
118 Ncca5d849695b436fbcf02e4c0bd34f30
119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001742245
120 https://doi.org/10.1038/sj.onc.1208954
121 schema:sdDatePublished 2022-05-20T07:23
122 schema:sdLicense https://scigraph.springernature.com/explorer/license/
123 schema:sdPublisher N8276f01ddd654aca983a241d9ef8b385
124 schema:url https://doi.org/10.1038/sj.onc.1208954
125 sgo:license sg:explorer/license/
126 sgo:sdDataset articles
127 rdf:type schema:ScholarlyArticle
128 N0b4693d27db04a09ad7d003ed4a549f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Apoptosis
130 rdf:type schema:DefinedTerm
131 N133a0b631b564fbcbbf042f8d67a42e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Humans
133 rdf:type schema:DefinedTerm
134 N16452f1431594c868a9ad0c28a22cd50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Transcription, Genetic
136 rdf:type schema:DefinedTerm
137 N17062abb28fc4cd796ae5703bf198aed schema:name doi
138 schema:value 10.1038/sj.onc.1208954
139 rdf:type schema:PropertyValue
140 N234d7557161c494f89fe06a3c0bdbb1b rdf:first sg:person.014442031637.81
141 rdf:rest rdf:nil
142 N2385cbdae07543e9885cfdaa897845c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Imidazoles
144 rdf:type schema:DefinedTerm
145 N2879626b51564f6f82ebd94ec267dbb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Antineoplastic Agents
147 rdf:type schema:DefinedTerm
148 N3461d55cc1114354b769b84d26aaa5d0 schema:issueNumber 55
149 rdf:type schema:PublicationIssue
150 N3946abb3c5174223a7a15d9faaede197 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Cell Line, Tumor
152 rdf:type schema:DefinedTerm
153 N45f77158cfd7437687aa4930f188469e schema:name dimensions_id
154 schema:value pub.1001742245
155 rdf:type schema:PropertyValue
156 N51e436e205fc4d2ca1679b1499ab3958 rdf:first sg:person.01016673065.20
157 rdf:rest N8007a6408cbf4ce1952821abee597af3
158 N51f71d7481b047efafd5414bbf0adac2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Antigens, CD20
160 rdf:type schema:DefinedTerm
161 N6563b4d65eca4361b9692a1812cd6e63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name p38 Mitogen-Activated Protein Kinases
163 rdf:type schema:DefinedTerm
164 N8007a6408cbf4ce1952821abee597af3 rdf:first sg:person.0757645323.30
165 rdf:rest N234d7557161c494f89fe06a3c0bdbb1b
166 N8276f01ddd654aca983a241d9ef8b385 schema:name Springer Nature - SN SciGraph project
167 rdf:type schema:Organization
168 N87d21fbfea534619af5f4068928e69c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Cell Survival
170 rdf:type schema:DefinedTerm
171 N9a283ab4e3d047209a160299bbcd9a44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Antibodies, Monoclonal
173 rdf:type schema:DefinedTerm
174 Nb2ea058f213d4271aefcd43d3dba6f5b schema:volumeNumber 24
175 rdf:type schema:PublicationVolume
176 Nb3fb60e3c1fe42a9b37f329defb7c3e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Enzyme Inhibitors
178 rdf:type schema:DefinedTerm
179 Nb99735ff2e524ff0bd0ce5e220ae35a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Rituximab
181 rdf:type schema:DefinedTerm
182 Nbef55dd5c958499dbea51fefede95395 rdf:first sg:person.01171343223.95
183 rdf:rest N51e436e205fc4d2ca1679b1499ab3958
184 Ncca5d849695b436fbcf02e4c0bd34f30 schema:name pubmed_id
185 schema:value 16103877
186 rdf:type schema:PropertyValue
187 Ncd09f32aa3464c4cb980158f70e5a76d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name NF-kappa B
189 rdf:type schema:DefinedTerm
190 Ne4348b5870494e069dd5f3396391c916 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Antibodies, Monoclonal, Murine-Derived
192 rdf:type schema:DefinedTerm
193 Ne49c3ef878b84d5eab988d05472c5d08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Burkitt Lymphoma
195 rdf:type schema:DefinedTerm
196 Ne8aa938a8703469482d193d8bad2c97c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Lymphoma, B-Cell
198 rdf:type schema:DefinedTerm
199 Neea33dfd643e49efae92bdf33118fac2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Lymphoma, AIDS-Related
201 rdf:type schema:DefinedTerm
202 Nf1fb6ff0ed774bb3ad15e94e38cc0b0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Gene Expression Regulation, Neoplastic
204 rdf:type schema:DefinedTerm
205 Nf51c62542b40466d9fbe9c6a2af434c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Pyridines
207 rdf:type schema:DefinedTerm
208 Nfa5d939125df4920bc7794a0b548cb02 rdf:first sg:person.01123230023.51
209 rdf:rest Nbef55dd5c958499dbea51fefede95395
210 Nff97f6cfde6d44d197e2db2ff0a7338f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name fas Receptor
212 rdf:type schema:DefinedTerm
213 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
214 schema:name Medical and Health Sciences
215 rdf:type schema:DefinedTerm
216 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
217 schema:name Clinical Sciences
218 rdf:type schema:DefinedTerm
219 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
220 schema:name Oncology and Carcinogenesis
221 rdf:type schema:DefinedTerm
222 sg:grant.2354610 http://pending.schema.org/fundedItem sg:pub.10.1038/sj.onc.1208954
223 rdf:type schema:MonetaryGrant
224 sg:grant.2438693 http://pending.schema.org/fundedItem sg:pub.10.1038/sj.onc.1208954
225 rdf:type schema:MonetaryGrant
226 sg:journal.1097543 schema:issn 0950-9232
227 1476-5594
228 schema:name Oncogene
229 schema:publisher Springer Nature
230 rdf:type schema:Periodical
231 sg:person.01016673065.20 schema:affiliation grid-institutes:grid.19006.3e
232 schema:familyName Jazirehi
233 schema:givenName Ali R
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016673065.20
235 rdf:type schema:Person
236 sg:person.01123230023.51 schema:affiliation grid-institutes:grid.419157.f
237 schema:familyName Vega
238 schema:givenName Mario I
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123230023.51
240 rdf:type schema:Person
241 sg:person.01171343223.95 schema:affiliation grid-institutes:grid.419157.f
242 schema:familyName Huerta-Yepez
243 schema:givenName Sara
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171343223.95
245 rdf:type schema:Person
246 sg:person.014442031637.81 schema:affiliation grid-institutes:grid.19006.3e
247 schema:familyName Bonavida
248 schema:givenName Benjamin
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014442031637.81
250 rdf:type schema:Person
251 sg:person.0757645323.30 schema:affiliation grid-institutes:grid.19006.3e
252 schema:familyName Garban
253 schema:givenName Hermes
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757645323.30
255 rdf:type schema:Person
256 sg:pub.10.1007/bf02982645 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011206446
257 https://doi.org/10.1007/bf02982645
258 rdf:type schema:CreativeWork
259 sg:pub.10.1007/s002620050016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035594402
260 https://doi.org/10.1007/s002620050016
261 rdf:type schema:CreativeWork
262 sg:pub.10.1023/a:1011158021749 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005577705
263 https://doi.org/10.1023/a:1011158021749
264 rdf:type schema:CreativeWork
265 sg:pub.10.1038/sj.leu.2401369 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018668097
266 https://doi.org/10.1038/sj.leu.2401369
267 rdf:type schema:CreativeWork
268 sg:pub.10.1038/sj.onc.1207336 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011264195
269 https://doi.org/10.1038/sj.onc.1207336
270 rdf:type schema:CreativeWork
271 sg:pub.10.1038/sj.onc.1207655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032441334
272 https://doi.org/10.1038/sj.onc.1207655
273 rdf:type schema:CreativeWork
274 sg:pub.10.1038/sj.onc.1208349 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005063354
275 https://doi.org/10.1038/sj.onc.1208349
276 rdf:type schema:CreativeWork
277 grid-institutes:grid.19006.3e schema:alternateName Department of Microbiology, Immunology and Molecular Genetics, University of California, 10833 Le Conte Avenue, A2-060 CHS, 90095, Los Angeles, CA, USA
278 Department of Molecular and Medical Pharmacology, Jonnson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, 90095, Los AngelesCA, USA
279 schema:name Department of Microbiology, Immunology and Molecular Genetics, University of California, 10833 Le Conte Avenue, A2-060 CHS, 90095, Los Angeles, CA, USA
280 Department of Molecular and Medical Pharmacology, Jonnson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, 90095, Los AngelesCA, USA
281 rdf:type schema:Organization
282 grid-institutes:grid.419157.f schema:alternateName Unidad de Investigaction Medica en Inmunologia e Infectologia, Hospital de Infectologia, CMN ‘La Raza’, IMSS, Mexico
283 schema:name Department of Microbiology, Immunology and Molecular Genetics, University of California, 10833 Le Conte Avenue, A2-060 CHS, 90095, Los Angeles, CA, USA
284 Unidad de Investigaction Medica en Inmunologia e Infectologia, Hospital de Infectologia, CMN ‘La Raza’, IMSS, Mexico
285 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...